Clinic
Houston Northwest Operating Company, LLC
Houston Northwest Operating Company, LLC was paid $18.38M by Medicaid between Jan 2020 and Dec 2024, across 76 billing codes. Its largest line is 99284, emergency room visit (serious) — 43% of everything it billed.
33Billing provider infoHOUSTON NORTHWEST OPERATING COMPANY, LLC
HOUSTON, TX 77090
HOUSTON, TX 77090
33aNPI1740450121assigned 03/03/2008
33bProvider typeUrgent Care Clinic/Center
28Total paid$18.38M
24GClaims217,147
24DCodes billed76
24AFirst – last monthJan 2020 – Dec 2024
Compared with peers
Next to other Urgent Care Clinic/Center providers in Texas
Rank by total paid#4 of 151
Median peer was paid$125K
This provider vs. median147×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 7,705 | $982K | |
| 2021 | 44,311 | $4.35M | |
| 2022 | 59,755 | $4.22M | |
| 2023 | 70,981 | $5.70M | |
| 2024incomplete | 34,395 | $3.13M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 43% | 19,312 | 18,140 | $7.95M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 41% | 30,818 | 29,841 | $7.51M |
| 71045 | Radiologic examination, chest; single view | 2.1% | 13,194 | 12,746 | $381K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 1.3% | 957 | 931 | $248K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 1,081 | 1,056 | $241K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 6,764 | 6,463 | $219K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.2% | 1,088 | 905 | $214K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 4,755 | 4,461 | $203K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.0% | 12,561 | 11,714 | $186K |
| 59025 | Fetal non-stress test | <1% | 4,180 | 3,377 | $168K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | <1% | 922 | 818 | $127K |
| 85027 | <1% | 21,665 | 20,047 | $121K |
64 more codes
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 7,892 | $108K |
| 81001 | <1% | 16,587 | $104K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,418 | $73K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 5,356 | $70K |
| 80053 | Comprehensive metabolic panel | <1% | 4,167 | $70K |
| 76801 | <1% | 497 | $46K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 741 | $41K |
| 36415 | Collection of venous blood by venipuncture | <1% | 25,501 | $30K |
| 80076 | <1% | 4,390 | $29K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 203 | $18K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,842 | $17K |
| 86403 | <1% | 1,656 | $17K | |
| 86850 | <1% | 1,232 | $16K | |
| 83690 | <1% | 3,825 | $16K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 513 | $16K |
| 84703 | <1% | 3,254 | $16K | |
| 93975 | <1% | 66 | $15K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 132 | $14K |
| 84484 | <1% | 2,913 | $13K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 462 | $11K |
| 84702 | <1% | 1,143 | $11K | |
| 87077 | <1% | 1,206 | $6K | |
| 87430 | <1% | 1,640 | $6K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 576 | $6K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 119 | $5K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 482 | $4K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 294 | $4K |
| 86900 | <1% | 1,443 | $3K | |
| 81025 | <1% | 347 | $3K | |
| 84112 | <1% | 87 | $3K | |
| 74018 | <1% | 50 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 284 | $3K |
| 86901 | <1% | 1,432 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 615 | $779.73 |
| 82248 | <1% | 905 | $779.46 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 15 | $587.26 |
| 83880 | <1% | 163 | $542.36 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 21 | $531.27 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 144 | $498.34 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 28 | $348.85 |
| 83735 | <1% | 211 | $275.83 | |
| 80320 | <1% | 43 | $264.69 | |
| 83605 | <1% | 40 | $263.75 | |
| 86141 | <1% | 42 | $197.78 | |
| 76818 | <1% | 14 | $180.06 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 312 | $148.01 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 27 | $146.27 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 319 | $145.77 |
| 85610 | <1% | 83 | $52.62 | |
| 81003 | <1% | 50 | $43.42 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 48 | $38.47 |
| 85730 | <1% | 55 | $30.30 | |
| J3490 | Unclassified drugs | <1% | 58 | $24.34 |
| 87040 | <1% | 13 | $17.34 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 15 | $12.52 |
| 87420 | <1% | 15 | $11.91 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 32 | $1.30 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 42 | $0.81 |
| A9270 | Non-covered item or service | 0% | 714 | $0.00 |
| 82043 | 0% | 13 | $0.00 | |
| 82570 | 0% | 13 | $0.00 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 14 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 23 | $0.00 |
| 84550 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWALKER, TAYLOR (CFO)
| Provider | Location | Paid |
|---|---|---|
| Northwest Medical Center INC | Margate, FL | $7.93M |
| HH Health System - Marshall LLC | Boaz, AL | $6.91M |
| HH Health System - Marshall LLC | Guntersville, AL | $954K |
| Marshall Medical Center South | Boaz, AL | $771K |
| Northeast Alabama Vascular and Vein Specialist | Albertville, AL | $26K |
| Neurology of Marshall County | Guntersville, AL | $13K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.